Global Corporate Venturing: Healthcare Innovation

Global Corporate Venturing: Healthcare Innovation

Penetration of CVC by Industry

Source: BCG, October 2012, analysing Global Corporate Venturing’s data

New health funds and commitments

• GSK’s $50m bioelectronic fund and LP commitment to Kurma Biofund II

• Stanford-StartX• Cipla incubator• BI joins Rockspring• Amgen and Novartis partner with Atlas• Bayer and Roche to QB3• MS Ventures doubles to €100m• Quintiles’ NovaQuestSource: Sample selected www.GlobalCorporat Venturing.com in 2013

Q2 Fundraising and Trends

ParentCorporate Venturing Unit/Fund Size Parent's Region Sector

TataTata Opportunities Fund $600m Asia Industrial

Unilever Unllever Ventures $450m Europe Consumer

SAP Hana Fund $250m* Europe IT

ShellShell Technology Ventures $100ms* Europe Energy

Merck MS Ventures €100m* Europe Health

Grupo RBS e.Bricks Digital $100m RoW IT

Infosys Fund $100m Asia IT

Giant Interactive Group Pleb Dream Fund RMB1bn ($161m)  Asia Media

Intel Perceptual fund $100m US IT

Quintiles NovaQuest $80m US Health

Source: Global Corporate Venturing* expansion of existing fund

Healthcare CVC’s narcissism

Source: BCG, October 2012, analysing Global Corporate Venturing’s 1,300 deals

Source: Global

Corporate Venturing

2011-13 Deal

Activity

Source: Global Corporate Venturing

Q2 2013 activity

Source: Global Corporate Venturing

Q2 Deal Activity

• 246 investments worth $5bn• 40 exits – IPOs picking up by number• M&A from portfolio companies up by a third• Series A leads by number of deals• IT most active, healthcare rebounds,• Asia and Europe increasing but US leads

“A global, multimedia publishing group dedicated to serving the intermediaries directing funding to entrepreneurs in the innovation

economy.”

Contact: James Mawson, founder and editor-in-chief Jmawson@globalcorporateventuring.com+1 650 906 1356 (US main) or +44 (0) 7971655590 (UK)